Pediatric Neuroinflammatory and Neuropsychiatric Syndromes Associated with Dupilumab Treatment for Atopic Dermatitis.
Dupilumab treatment in children with atopic dermatitis may be associated with neuroinflammatory syndromes, warranting caution and further investigation.
Where it sits
this study against the rest of the kpv corpusSummary and findings
This study reports on neuroinflammatory syndromes in 4 children treated with dupilumab for atopic dermatitis. Behavioral changes, language impairment, and neurodiagnostic abnormalities were observed 2-6 months post-treatment initiation. Three children showed improvement after drug discontinuation and immunomodulatory therapy.
Abstract
Dupilumab, a monoclonal antibody blocking interleukin-4/interleukin-13 signaling, was associated with neuroinflammatory syndromes in 4 children treated for atopic dermatitis. Individuals exhibited behavioral changes, language impairment, and neurodiagnostic abnormalities 2-6 months after treatment initiation. Three improved with drug discontinuation and immunomodulatory therapy; 1 with pre-existing X-linked adrenoleukodystrophy required stem cell transplantation.
Background
The paper addresses the potential neuroinflammatory and neuropsychiatric effects in children undergoing Dupilumab treatment for atopic dermatitis. Previous studies have indicated that Dupilumab may have various side effects, but specific neuropsychiatric outcomes in pediatric patients have not been extensively documented. This study aims to fill that gap by exploring these associations.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.